Lupin plans to launch 20 products in US in FY 2014-15
Lupin aims to sharpen its focus on less-competitive segments with the new launches.
New Delhi, August 5, 2013: Drug firm Lupin plans to strengthen its US pipeline further by launching 20 new products during 2014-15. The company plans to sharpen its focus on less-competitive segments like oral contraceptives ad ophthalmology.
It is interesting to note here that the company has 26 first-to-file opportunities in the US market out of which 12 are exclusive opportunities. The oral contraceptive market in the US is estimated to be around US$ 5 billion and is growing at a rate of 10 per cent annually.
Lupin's current ANDA filings for OCs stand at 32 and the company is similarly targeting ophthalmology and dermatological segments as well. The company has already done over 10-12 filings with the USFDA for ophthalmological products.
It may be noted here that the US and Europe formulation sales of the company grew by 47 per cent to Rs 4,005.1 crore during 2012-13 contributing 42 per cent to overall sales.